Last reviewed · How we verify

Topiramate (drug) — Competitive Intelligence Brief

Topiramate (drug) (Topiramate (drug)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfamate-substituted monosaccharide. Area: Neurology.

phase 3 Sulfamate-substituted monosaccharide Voltage-dependent sodium channels, GABA receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Topiramate (drug) (Topiramate (drug)) — Erasmus Medical Center. Topiramate is a sulfamate-substituted monosaccharide that acts as a voltage-dependent sodium channel blocker and GABA receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Topiramate (drug) TARGET Topiramate (drug) Erasmus Medical Center phase 3 Sulfamate-substituted monosaccharide Voltage-dependent sodium channels, GABA receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfamate-substituted monosaccharide class)

  1. Erasmus Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topiramate (drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/topiramate-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: